Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial — MND-SMART  

Motor Neuron Disease, Amyotrophic Lateral Sclerosis Clinical Trial

Official title: Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

Status Recruiting

Clinical Trial Summary

MND-SMART is investigating whether selected drugs can slow down the progression of motor neurone disease (MND) and improve survival. The study is 'multi-arm' meaning more than one treatment will be tested at the same time. The trial started with 3 arms; drug 1 (memantine), drug 2 (trazodone) and placebo (dummy drug). A third drug, amantadine, was added in April 2023. The first two drugs, memantine and trazodone, were removed from the trial in September 2023 due to lack of benefit. The trial currently has 2 recruiting arms; amantadine and placebo. This allows the evaluation of each drug versus placebo. Participants will be randomly allocated to either of the recruiting arms. Medicines being tested are already approved for use in other conditions. MND-SMART has an 'adaptive' design. This means medicines being studied can change according to emerging results. Treatments shown to be ineffective can be dropped and new drugs can be added over the duration of the study. This will allow many treatments, over time, to be efficiently and definitively evaluated. The medicines being tested have been selected following a rigorous process involving a systematic, unbiased, and comprehensive review of past clinical trials data, as well as information from pre-clinical research (studies in laboratories), for MND and other related neurodegenerative disorders. Drugs have been ranked for inclusion in MND-SMART by a group of independent MND experts according to set criteria. These include consideration of how the drugs work, their safety profiles, and the quality of previous studies. New drugs will be selected for investigation in MND-SMART based on continuous review of constantly updated scientific evidence as well as findings from state-of-the-art human stem cell based drug discovery platforms. These can be added by substantial amendment to the protocol.

Clinical Trial Description

For further information, please visit: https://mnd-smart.org/ ;

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Motor Neuron Disease, Amyotrophic Lateral Sclerosis

• NCT number: NCT04302870
• Study type: Interventional
• Source: University of Edinburgh
• Contact: Professor Chandran
• Phone: 0131 465 9612
• Email: siddharthan.chandran@ed.ac.uk
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: February 27, 2020
• Completion date: December 2026